Viking Therapeutics rises after it starts late-stage study of obesity drug

Viking Therapeutics

25/06/2025 13:13

** Shares of drug developer Viking Therapeutics VKTX.O rise 1.1% to $27.25 premarket

** VKTX says it has started a late-stage study of its experimental GLP-1 obesity drug candidate, VK2735, in both oral and injectable formulations

** The late-stage study will test the drug in adults with obesity and in overweight or obese adults with type 2 diabetes over 78 weeks, company says

** As of last close, VKTX stock down 33% YTD

 (Reporting by Padmanabhan Ananthan)

 ((Padmanabhan.Ananthan@thomsonreuters.com))